在资源有限的情况下，治疗aml的最佳方法是什么

IF 1.8 Q3 HEMATOLOGY

Hematology, Transfusion and Cell Therapy Pub Date : 2025-07-01 DOI:10.1016/j.htct.2025.103870

Mipsang Lama

{"title":"在资源有限的情况下，治疗aml的最佳方法是什么","authors":"Mipsang Lama","doi":"10.1016/j.htct.2025.103870","DOIUrl":null,"url":null,"abstract":"<div><div>AML itself is one of the worst prognostic hematological malignancies which has to be managed timely, adequately and aggressively to get on top of it. Such, kind of patients will need intensive chemotherapy therapy (3+7, Flag IDA) followed by allogeneic SCT. That is why it is challenging to manage such cases in resource limited setting. Due to constant development of new drugs treatment of such patients with azacytidine and venetoclax have been lot easier. With these drugs we are being able to put patients in remission with less toxicities, and low cost as compared to intensive chemotherapy.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 ","pages":"Article 103870"},"PeriodicalIF":1.8000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"WHICH IS THE BEST TREATMENT FOR AML WITH RESTRICTED RESOURCES\",\"authors\":\"Mipsang Lama\",\"doi\":\"10.1016/j.htct.2025.103870\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>AML itself is one of the worst prognostic hematological malignancies which has to be managed timely, adequately and aggressively to get on top of it. Such, kind of patients will need intensive chemotherapy therapy (3+7, Flag IDA) followed by allogeneic SCT. That is why it is challenging to manage such cases in resource limited setting. Due to constant development of new drugs treatment of such patients with azacytidine and venetoclax have been lot easier. With these drugs we are being able to put patients in remission with less toxicities, and low cost as compared to intensive chemotherapy.</div></div>\",\"PeriodicalId\":12958,\"journal\":{\"name\":\"Hematology, Transfusion and Cell Therapy\",\"volume\":\"47 \",\"pages\":\"Article 103870\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hematology, Transfusion and Cell Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2531137925001385\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology, Transfusion and Cell Therapy","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2531137925001385","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

急性髓性白血病本身是预后最差的血液系统恶性肿瘤之一，必须及时、充分和积极地进行管理才能控制它。这类患者需要强化化疗（3+7,Flag IDA），然后进行同种异体SCT。这就是为什么在资源有限的情况下管理这类案件具有挑战性的原因。由于新药的不断发展，治疗这类患者用阿扎胞苷和维托克拉克斯已经容易得多。与强化化疗相比，使用这些药物，我们能够以更少的毒性和更低的成本缓解患者的病情。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

WHICH IS THE BEST TREATMENT FOR AML WITH RESTRICTED RESOURCES

AML itself is one of the worst prognostic hematological malignancies which has to be managed timely, adequately and aggressively to get on top of it. Such, kind of patients will need intensive chemotherapy therapy (3+7, Flag IDA) followed by allogeneic SCT. That is why it is challenging to manage such cases in resource limited setting. Due to constant development of new drugs treatment of such patients with azacytidine and venetoclax have been lot easier. With these drugs we are being able to put patients in remission with less toxicities, and low cost as compared to intensive chemotherapy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊